Quest Diagnostics Incorporated, a global provider of diagnostic tests and information services, has received a neutral rating from UBS.
The company generates the majority of its revenue, around 97%, from tests and diagnostic services, including routine clinical tests, genetic tests, and advanced diagnostic and anatomic pathology services.
The remaining 3% of net sales comes from other activities. Quest Diagnostics is a key player in the healthcare sector, delivering essential diagnostic solutions to patients and healthcare professionals. Despite its strong portfolio, UBS maintains a cautious outlook on the company's stock performance in the near term.